Advanced Filters
noise
Found 842 clinical trials
Y Yi Tang, M.D., Ph.D.

Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease

The goal of this study is to explore the efficacy and safety of near-infrared light combined with lecanemab in patients with mild Alzheimer's disease (AD). This study will employ a randomized, double-blind, sham-controlled method with an open-label extension phase. This trial contains the core phase and an extension phase. During …

50 - 90 years of age All Phase N/A
K Kimberlee Wheeler

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. …

55 - 80 years of age All Phase 2

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

50 - 85 years of age All Phase 2
S Svein Kjosaviki, MD PhD

Blood-based Biomarkers for Diagnosis of Alzheimer's

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests …

40 - 100 years of age All Phase N/A
E Erin Frank

Clinical Trial on Agitation in Alzheimer's Dementia

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

60 years of age All Phase 2
D Diane Chan, MD/PhD

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid …

65 - 100 years of age All Phase N/A
K Kenji Aoki, BA

Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found …

55 - 90 years of age All Phase N/A
T Tae-Ho Lee, PhD

The Role of the Locus Coeruleus in Age-related Distractibility

A growing body of research has highlighted the importance of frontal regions, at both the functional and structural levels, in age-related declines in attentional and cognitive processing. However, the underlying neurobiological pathophysiological changes in the brain that contribute to these declines are still largely unclear. The objective of this proposal …

18 - 75 years of age All Phase N/A
C Cristina Toedebusch, BS

Sleep Trial to Prevent Alzheimer's Disease

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

65 years of age All Phase 2
S Suson (Sue) Walsh

MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics

The Researchers are trying to test a MR imaging method for detection of Cerebral Spinal Fluid (CSF) flow in the brain to help diagnosis and better understand diseases that affect brain function.

18 years of age All Phase N/A

Simplify language using AI